Death or bronchopulmonary dysplasia at 36 weeks PMA · preterm infants at risk for bronchopulmonary dysplasia
Pulse may leads to higher death or bronchopulmonary dysplasia at 36 weeks' PMA compared with continuous dexamethasone therapy (low certainty).
1 finding from 1 review
Death or abnormal neurodevelopmental outcome (various definitions) · preterm infants at risk for bronchopulmonary dysplasia
It is very uncertain whether pulse changes death or abnormal neurodevelopmental outcome (various definitions) compared with continuous dexamethasone therapy (very low certainty).
1 finding from 1 review
Functional ability in targeted activities: personal goals ‐ performance (participant self‐report) · people with mild‐to‐moderate dementia (at the end of therapy)
1 finding from 1 review
Functional ability in targeted activities: personal goals ‐ performance (informant report of participant) · people with mild‐to‐moderate dementia (at the end of therapy)
1 finding from 1 review
Functional ability · people with mild‐to‐moderate dementia (at the end of therapy)
1 finding from 1 review
Self‐efficacy · people with mild‐to‐moderate dementia (at the end of therapy)
1 finding from 1 review
Mood: depression (participant self‐report) · people with mild‐to‐moderate dementia (at the end of therapy)
1 finding from 1 review
QoL · people with mild‐to‐moderate dementia (at the end of therapy)
1 finding from 1 review
Quality of life: psychological (care partner self‐report) · people with mild‐to‐moderate dementia (at the end of therapy)
1 finding from 1 review
Intervention not reported
Component · adults (aged ≥ 18 years) who smoked cigarettes Components: components of pharmacological and e‐cigarette (EC) interventions for smoking…
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Varenicline · adults (aged ≥ 18 years) who smoked cigarettes Components: components of pharmacological and e‐cigarette (EC) interventions for smoking…
The intervention showed no clear difference in varenicline (low certainty).
1 finding from 1 review
Intervention not reported
Cytisine · adults (aged ≥ 18 years) who smoked cigarettes Components: components of pharmacological and e‐cigarette (EC) interventions for smoking…
The intervention showed no clear difference in cytisine (low certainty).
1 finding from 1 review
Intervention not reported
Nicotine patch · adults (aged ≥ 18 years) who smoked cigarettes Components: components of pharmacological and e‐cigarette (EC) interventions for smoking…
The intervention showed no clear difference in nicotine patch (low certainty).
1 finding from 1 review
Intervention not reported
Fast‐acting NRT (nicotine other) · adults (aged ≥ 18 years) who smoked cigarettes Components: components of pharmacological and e‐cigarette (EC) interventions for smoking…
The intervention showed no clear difference in fast‐acting NRT (nicotine other) (low certainty).
1 finding from 1 review
Intervention not reported
Nicotine EC · adults (aged ≥ 18 years) who smoked cigarettes Components: components of pharmacological and e‐cigarette (EC) interventions for smoking…
The intervention showed no clear difference in nicotine EC (low certainty).
1 finding from 1 review
Intervention not reported
Non‐nicotine/placebo EC · adults (aged ≥ 18 years) who smoked cigarettes Components: components of pharmacological and e‐cigarette (EC) interventions for smoking…
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Bupropion · adults (aged ≥ 18 years) who smoked cigarettes Components: components of pharmacological and e‐cigarette (EC) interventions for smoking…
The intervention showed no clear difference in bupropion (moderate certainty).
1 finding from 1 review
Intervention not reported
Nortriptyline · adults (aged ≥ 18 years) who smoked cigarettes Components: components of pharmacological and e‐cigarette (EC) interventions for smoking…
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
All‐cause mortality ( · people with CLI who were not suitable for revascularisation and showed no improvement in response to the best standard therapy
It is very uncertain whether intramuscular injection of bone marrow mononuclear cells (BMMNC) changes all‐cause mortality ( compared with control (very low certainty).
1 finding from 1 review
Reduction in pain Various scales including VAS, PISQ; scales ranged from 0 to 4/10/100, where 0 = no pain ( · people with CLI who were not suitable for revascularisation and showed no improvement in response to the best standard therapy
1 finding from 1 review